Our result that the APOE ε2 allele may confer protection against cognitive decline for cancer survivors selected to receive chemotherapy adds a new dimension to the body of evidence supporting a role of APOE genotype broadly and strengthens evidence suggesting parallels between CRCD and AD (9,12,15,31,53). This evidence concerns the gene APOE and cancer.